Cargando…

Comprehensive Preclinical Assessment of ADVM-022, an Intravitreal Anti-VEGF Gene Therapy for the Treatment of Neovascular AMD and Diabetic Macular Edema

Inhibition of vascular endothelial growth factor is the mode of action for several approved therapies, including aflibercept, for the treatment of neovascular age-related macular degeneration (nAMD) and diabetic macular edema (DME). Lack of compliance due to the frequent intravitreal dosing requirem...

Descripción completa

Detalles Bibliográficos
Autores principales:	Gelfman, Claire M., Grishanin, Ruslan, Bender, Kristina Oresic, Nguyen, Aivan, Greengard, Judith, Sharma, Pallavi, Nieves, Julio, Kiss, Szilárd, Gasmi, Mehdi
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Mary Ann Liebert, Inc., publishers 2021
Materias:	Original Articles
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8060718/ https://www.ncbi.nlm.nih.gov/pubmed/33835848 http://dx.doi.org/10.1089/jop.2021.0001

Ejemplares similares

Analysis of Aflibercept Expression in NHPs following Intravitreal Administration of ADVM-022, a Potential Gene Therapy for nAMD
por: Kiss, Szilárd, et al.
Publicado: (2020)

Long-Term Safety Evaluation of Continuous Intraocular Delivery of Aflibercept by the Intravitreal Gene Therapy Candidate ADVM-022 in Nonhuman Primates
por: Kiss, Szilárd, et al.
Publicado: (2021)

Preclinical Evaluation of ADVM-022, a Novel Gene Therapy Approach to Treating Wet Age-Related Macular Degeneration
por: Grishanin, Ruslan, et al.
Publicado: (2019)

Incidence of ocular hypertension after intravitreal injection of anti-VEGF agents in the treatment of neovascular AMD
por: Moraru, Andreea, et al.
Publicado: (2017)

Systemic pharmacokinetics following intravitreal injections of ranibizumab, bevacizumab or aflibercept in patients with neovascular AMD
por: Avery, Robert L, et al.
Publicado: (2014)

Choroidal Thickness Changes After Intravitreal Aflibercept Injections in Treatment-Naïve Neovascular AMD
por: Minnella, Angelo Maria, et al.
Publicado: (2022)

Short-term real-world outcomes following intravitreal brolucizumab for neovascular AMD: SHIFT study
por: Bulirsch, Louisa Maria, et al.
Publicado: (2022)

New Therapies of Neovascular AMD—Beyond Anti-VEGFs
por: Yerramothu, Praveen
Publicado: (2018)

Microvascular abnormalities and long-term efficacy after stereotactic radiotherapy under continued intravitreal anti-VEGF treatment for neovascular AMD
por: Hatz, Katja, et al.
Publicado: (2022)

Retrospective analysis of OCT parameters after intravitreal anti-VEGF inhibitors in neovascular AMD patients in a real-world setting
por: Lüke, Jan Niklas, et al.
Publicado: (2022)

The Architecture of Macular Neovascularizations Predicts Treatment Responses to Anti-VEGF Therapy in Neovascular AMD
por: Faatz, Henrik, et al.
Publicado: (2022)

New Therapies of Neovascular AMD beyond Anti-VEGF Injections
por: Gahn, Greggory M., et al.
Publicado: (2018)

Intravitreal Nesvacumab (Anti-Angiopoietin-2) Plus Aflibercept in Neovascular AMD: Phase 2 ONYX Randomized Trial
por: Heier, Jeffrey S., et al.
Publicado: (2022)

Mechanisms of FH Protection Against Neovascular AMD
por: Borras, Céline, et al.
Publicado: (2020)

The Impact of Diabetic Retinopathy on the Choriocapillaris in Neovascular AMD
por: Viggiano, Pasquale, et al.
Publicado: (2023)

Effect of aflibercept in insufficient responders to prior anti-VEGF therapy in neovascular AMD
por: Fassnacht-Riederle, Heidi, et al.
Publicado: (2014)

Anti-VEGF intervention in neovascular AMD: benefits and risks restated as natural frequencies
por: Clearkin, Louis, et al.
Publicado: (2019)

Effectiveness of intravitreal ranibizumab in exudative age-related macular degeneration (AMD): comparison between typical neovascular AMD and polypoidal choroidal vasculopathy over a 1 year follow-up
por: Matsumiya, Wataru, et al.
Publicado: (2013)

Aqueous Fluid Transcriptome Profiling Differentiates Between Non-Neovascular and Neovascular AMD
por: Kaidonis, Georgia, et al.
Publicado: (2023)

Improving treatment provision of Wet AMD with intravitreal ranibizumab
por: Ghazala, Fadi, et al.
Publicado: (2013)

Regulation of signaling events involved in the pathophysiology of neovascular AMD
por: Wang, Haibo, et al.
Publicado: (2016)

Gains in the current understanding of managing neovascular AMD with brolucizumab
por: Bodaghi, Bahram, et al.
Publicado: (2023)

Intravitreal Aflibercept as a Rescue Therapy for Retinal Neovascularization and Macular Edema due to Eales Disease
por: Hsia, Ning-Yi, et al.
Publicado: (2021)

Topographical Analysis of the Choriocapillaris Reperfusion After Loading Anti-VEGF Therapy in Neovascular AMD
por: Viggiano, Pasquale, et al.
Publicado: (2022)

Dihydroartemisinin Inhibits Laser-Induced Choroidal Neovascularization in a Mouse Model of Neovascular AMD
por: Li, Xun, et al.
Publicado: (2022)

Efficacy and tolerability of bilateral sustained-release dexamethasone intravitreal implants for the treatment of noninfectious posterior uveitis and macular edema secondary to retinal vein occlusion
por: Ryder, Steven J, et al.
Publicado: (2015)

Combination of AIBP, apoA-I, and Aflibercept Overcomes Anti-VEGF Resistance in Neovascular AMD by Inhibiting Arteriolar Choroidal Neovascularization
por: Zhang, Zhao, et al.
Publicado: (2022)

Genetic screening for neovascular AMD: cost effective…not so quick
por: Reichel, Elias
Publicado: (2015)

Switch to Aflibercept in the Treatment of Neovascular AMD: Long-Term Results
por: Neves Cardoso, Pedro, et al.
Publicado: (2017)

Trends in Real-World Neovascular AMD Treatment Outcomes in the UK
por: Mehta, Hemal, et al.
Publicado: (2020)

PRN Treatment of Neovascular AMD with Cycles of Three Monthly Injections
por: Banaee, Touka, et al.
Publicado: (2021)

Lentiviral delivered aflibercept OXB-203 for treatment of neovascular AMD
por: Iqball, Sharifah, et al.
Publicado: (2023)

Real-World Injection Frequency and Cost of Ranibizumab and Aflibercept for the Treatment of Neovascular Age-Related Macular Degeneration and Diabetic Macular Edema
por: Kiss, Szilárd, et al.
Publicado: (2020)

Intravitreal Combination of Dexamethasone Sodium Phosphate and Bevacizumab in The Treatment of Exudative AMD
por: Vakalis, N., et al.
Publicado: (2015)

Epidemiological and Clinical Baseline Characteristics as Predictive Biomarkers of Response to Anti-VEGF Treatment in Patients with Neovascular AMD
por: Tsilimbaris, Miltiadis K., et al.
Publicado: (2016)

Current and upcoming anti-VEGF therapies and dosing strategies for the treatment of neovascular AMD: a comparative review
por: Khanna, Saira, et al.
Publicado: (2019)

The effect of systemic levels of TNF-alpha and complement pathway activity on outcomes of VEGF inhibition in neovascular AMD
por: Khan, Adnan H., et al.
Publicado: (2021)

Brolucizumab and fluid in neovascular age-related macular degeneration (n-AMD)
por: Sharma, Ashish, et al.
Publicado: (2020)

Manifestations of intraocular inflammation over time in patients on brolucizumab for neovascular AMD
por: Khoramnia, Ramin, et al.
Publicado: (2021)

Importance of Anatomical Efficacy for Disease Control in Neovascular AMD: An Expert Opinion
por: Balaskas, Konstantinos, et al.
Publicado: (2021)

Cannot write session to /tmp/vufind_sessions/sess_8eva3k90r00q5cqhf0smikjndm